Concepedia

Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab

A. Michael Lincoff, James E. Tcheng, Robert M. Califf, Dean J. Kereiakes, Thomas A. Kelly, GERALD C. TIMMIS, Neal S. Kleiman, Joan E. Booth, Craig Balog, Catherine F. Cabot,

Circulation · 1999 · 157 citations · 15 references

DOI

Abstract

Acute reductions in ischemic events after percutaneous coronary intervention by abciximab are sustained over follow-up to at least 1 year. Early periprocedural myocardial infarctions suppressed by this therapy are associated with long-term mortality rates.

References

15

Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty

The EPIC Investigators · New England Journal of Medicine · 1994 · 2.6K citations · Full text

Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization

The EPILOG Investigators · New England Journal of Medicine · 1997 · 1.9K citations · Full text

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

T Epistent Investigators · The Lancet · 1998 · 1.4K citations

, , +9

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study

The Lancet · 1997 · 1.3K citations · Full text

, , +10

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

Eric J. Topol · The Lancet · 1998 · 1.1K citations

, , +9